Retrieve available abstracts of 16 articles: HTML format
Single Articles
January 2025
FEDORCHENKO SV, Klimenko Z, Martynovich T, Solianyk I, et al Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who
previously failed a regimen containing second-generation NS5A inhibitors with
sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks.
J Virol. 2025 Jan 22:e0184324. doi: 10.1128/jvi.01843. PubMedAbstract available
June 2024
LIU J, Ito M, Liu L, Nakashima K, et al Involvement of ribosomal protein L17 and Y-box binding protein 1 in the assembly
of hepatitis C virus potentially via their interaction with the 3' untranslated
region of the viral genome.
J Virol. 2024 Jun 20:e0052224. doi: 10.1128/jvi.00522. PubMedAbstract available
March 2024
TAMURA T, Yamamoto H, Ogino S, Morioka Y, et al A rapid and versatile reverse genetics approach for generating recombinant
positive-strand RNA viruses that use IRES-mediated translation.
J Virol. 2024;98:e0163823. PubMedAbstract available
February 2024
FRERICKS N, Brown RJP, Reinecke BM, Herrmann M, et al Unraveling the dynamics of hepatitis C virus adaptive mutations and their impact
on antiviral responses in primary human hepatocytes.
J Virol. 2024 Feb 6:e0192123. doi: 10.1128/jvi.01921. PubMedAbstract available
January 2024
CASIANO MATOS J, Harichandran K, Tang J, Sviridov DO, et al Hepatitis C virus E1 recruits high-density lipoprotein to support infectivity and
evade antibody recognition.
J Virol. 2024 Jan 4:e0084923. doi: 10.1128/jvi.00849. PubMedAbstract available
December 2023
HAGA Y, Meyer K, Sung MMH, Reagan EK, et al Hepatitis C virus modified sE2(F442NYT) as an antigen in candidate vaccine
facilitates human immune cell activation.
J Virol. 2023 Dec 12:e0180923. doi: 10.1128/jvi.01809. PubMedAbstract available
GOBRAN ST, Pagliuzza A, Khedr O, Fert A, et al DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people.
J Virol. 2023 Dec 5:e0110523. doi: 10.1128/jvi.01105. PubMedAbstract available
November 2023
BAJPAI PS, Collignon L, Solund C, Madsen LW, et al Full-length sequence analysis of hepatitis C virus genotype 3b strains and
development of an in vivo infectious 3b cDNA clone.
J Virol. 2023 Nov 21:e0092523. doi: 10.1128/jvi.00925. PubMedAbstract available
October 2023
LI Y, Yang Y, Li T, Wang Z, et al Activation of AIM2 by hepatitis B virus results in antiviral immunity that
suppresses hepatitis C virus during coinfection.
J Virol. 2023 Oct 3:e0109023. doi: 10.1128/jvi.01090. PubMedAbstract available
September 2023
NEPAL S, Holmstrom ED Single-molecule-binding studies of antivirals targeting the hepatitis C virus
core protein.
J Virol. 2023 Sep 29:e0089223. doi: 10.1128/jvi.00892. PubMedAbstract available
FELLENBERG J, Dubrau D, Isken O, Tautz N, et al Packaging defects in pestiviral NS4A can be compensated by mutations in NS2 and
NS3.
J Virol. 2023;97:e0057223. PubMedAbstract available
June 2023
PANIGRAHI M, Palmer MA, Wilson JA Enhanced Virus Translation Enables miR-122-Independent Hepatitis C Virus
Propagation.
J Virol. 2023 Jun 20:e0085821. doi: 10.1128/jvi.00858. PubMedAbstract available
AVULA K, Singh B, Samantaray S, Syed GH, et al The Early Secretory Pathway Is Crucial for Multiple Aspects of the Hepatitis C
Virus Life Cycle.
J Virol. 2023 Jun 20:e0018023. doi: 10.1128/jvi.00180. PubMedAbstract available
TOON K, Kalemera MD, Palor M, Rose NJ, et al GB Virus B and Hepatitis C Virus, Distantly Related Hepaciviruses, Share an Entry
Factor, Claudin-1.
J Virol. 2023 Jun 13:e0046923. doi: 10.1128/jvi.00469. PubMedAbstract available
ABE T, Marutani Y, Deng L, Matsui C, et al Hepatitis C Virus Disrupts Annexin 5-Mediated Occludin Integrity through
Downregulation of Protein Kinase Calpha (PKCalpha) and PKCeta Expression, Thereby Promoting
Viral Propagation.
J Virol. 2023 Jun 5:e0065523. doi: 10.1128/jvi.00655. PubMedAbstract available
April 2023
WOLFISBERG R, Holmbeck K, Billerbeck E, Thorselius CE, et al Molecular Determinants of Mouse Adaptation of Rat Hepacivirus.
J Virol. 2023;97:e0181222. PubMedAbstract available